Dave Daly’s board appointment is effective Nov. 10.
FORT MYERS — Cancer-focused genetic testing services firm NeoGenomics has named biosciences executive Dave Daly to its board.
Daly, with a board appointment effective Nov. 10, is currently the president and COO at Singular Genomics, a next generation sequencing and multi-omics technology platform company, according to the company’s website. Prior to Singular Genomics, Daly was CEO at Thrive Earlier Detection, a liquid biopsy-focused cancer screening company acquired by Exact Sciences Corporation for $2.15 billion earlier this year.
Daly, the company says, has also served in key leadership roles at Illumina where he was senior vice president and general manager of commercial operations for the Americas Region; Foundation Medicine where he was Chief Commercial Officer; Life Technologies where he led the oncology business unit; and Clarient where he served as Chief Commercial Officer. (NeoGenomics acquired Clarient, a unit of GE Healthcare Life Sciences, in a $310 million deal in 2016.)
NeoGenomics, which recently built a new headquarters in Fort Myers, had $444.44 million in revenue in 2020.